INTRA-CELLULAR THERAPIES INC (ITCI)

Company Profile

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 610 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Company Info

INTRA-CELLULAR THERAPIES INC

135 Route 202/206, Suite 6

Bedminster NEW JERSEY 10016

P: 16464409333

CEO: Sharon Mates

Employees: 610

Website: https://www.intracellulartherapies.com/